Inactivated Influenza Vaccine Global Market Report 2025
상품코드:1760565
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
불활성화 인플루엔자 백신 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 8.5%의 성장률로 99억 9,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 4가 백신에 대한 수요 증가, 예방접종 프로그램 확대, 전염병 예방에 대한 관심 증가, 백신 제조 기술 발전, 백신에 대한 전 세계 접근성 증가 등에 기인하는 것으로 보입니다. 이 기간 동안 주요 동향으로는 세포 기반 백신 제조로의 전환, 보조제제제 채택 확대, 독감 백신과 코로나19 부스터의 통합, 신흥 시장에서 수요 증가, 개인 맞춤형 백신 전략 개발 등을 꼽을 수 있습니다.
정부의 백신 접종 프로그램의 성장으로 불활성화 인플루엔자 백신 시장이 크게 성장하고 있습니다. 공중보건에 대한 인식이 높아짐에 따라 각국 정부는 예방접종에 대한 노력을 강화하고 있으며, 이는 백신에 대한 수요 증가와 보다 편리한 예방접종 서비스 제공으로 이어지고 있습니다. 이러한 프로그램은 고위험군에게 비활성화 독감 백신을 무료 또는 보조금으로 제공하여 백신 접종을 널리 보급하고 독감의 계절적 부담을 줄이는 데 중요한 역할을 하고 있습니다. 예를 들어, 2023년 12월 영국 국민보건서비스(NHS)는 새로운 예방접종 전략을 도입하여, 특히 소외된 지역사회에 대한 예방접종 보급 활동을 개선하는 것을 목표로 하고 있습니다. 이 전략은 예방접종 접근성을 확대하고 공중 보건을 더욱 증진시키는 것을 목표로 하고 있으며, 비활성화 독감 백신 시장의 성장을 가속할 것으로 예측됩니다.
불활성화 인플루엔자 백신 시장의 주요 기업들은 4가 백신 개발에 점점 더 많은 노력을 기울이고 있습니다. 4가 백신은 4가지의 서로 다른 독감 바이러스 균주를 방어하도록 설계되어 보다 광범위한 방어력을 제공하고 백신의 효능을 향상시킵니다. 예를 들어, 2025년 2월 인도에 본사를 둔 제약회사 자이더스 생명과학(Zydus Lifesciences)는 4가 불활성화 인플루엔자 백신인 백시플루-4(VaxiFlu-4)를 출시하여 4가지 독감 바이러스 균주에 대한 예방 효과를 제공했습니다. 이 백신은 인플루엔자 A형과 B형을 모두 커버하여 백신 불일치 위험을 줄이고, 계절성 독감 유행에 대한 예방 효과를 높이며, 지역 역학 동향에 따라 면역반응을 조절합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 불활성화 인플루엔자 백신 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 불활성화 인플루엔자 백신 시장 : 성장률 분석
세계의 불활성화 인플루엔자 백신 시장 실적 : 규모와 성장, 2019-2024년
세계의 불활성화 인플루엔자 백신 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계 불활성화 인플루엔자 백신 전체 시장(TAM)
제6장 시장 세분화
세계의 불활성화 인플루엔자 백신 시장 : 백신 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
3가 불활성화 인플루엔자 백신(TIIV)
4가 불활성화 인플루엔자 백신(QIIV)
세계의 불활성화 인플루엔자 백신 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
소아
청년기
성인
고령자
세계의 불활성화 인플루엔자 백신 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
공중위생 클리닉
세계의 불활성화 인플루엔자 백신 시장 : 최종사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
의료 제공자
개인
정부기관
제약회사
세계의 불활성화 인플루엔자 백신 시장 : 3가 불활성화 인플루엔자 백신(TIIV), 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
계란 기반 3가 불활성화 인플루엔자 백신
세포 기반 3가 불활성화 인플루엔자 백신
항원보강제 첨가 3가 불활성화 인플루엔자 백신
고용량 3가 불활성화 인플루엔자 백신
세계의 불활성화 인플루엔자 백신 시장 : 4가 불활성화 인플루엔자 백신(QIIV), 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
계란 기반 4가 불활성화 인플루엔자 백신
세포 기반 4가 불활성화 인플루엔자 백신
항원보강제 첨가 4가 불활성화 인플루엔자 백신
재조합 4가 불활성화 인플루엔자 백신
소아 4가 불활성화 인플루엔자 백신
제7장 지역별/국가별 분석
세계의 불활성화 인플루엔자 백신 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 불활성화 인플루엔자 백신 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
불활성화 인플루엔자 백신 시장 : 경쟁 구도
불활성화 인플루엔자 백신 시장 : 기업 개요
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi S.A. : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Abbott Laboratories
Novartis International
GlaxoSmithKline plc
Viatris Inc.
CSL
Zydus Lifesciences Limited
Sinovac Biotech Ltd.
Bharat Biotech International Limited
Dalian Aleph Biomedical Co. Ltd.
Hualan Biological Bacterin Co. Ltd
Changchun Biological
Jiangsu gdk Biotechnology Co., Ltd.
KM Biologics
JoinHub Pharma
Pharmika India Private Limited
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
불활성화 인플루엔자 백신 시장, 2029년 : 새로운 기회를 제공하는 국가
불활성화 인플루엔자 백신 시장, 2029년 : 새로운 기회를 제공하는 부문
불활성화 인플루엔자 백신 시장, 2029년 : 성장 전략
시장 동향에 근거한 전략
경쟁 전략
제36장 부록
LSH
영문 목차
영문목차
Inactivated influenza vaccines are flu vaccines that contain viruses that have been killed or inactivated. These vaccines stimulate the immune system to produce antibodies against the influenza virus and are administered via injection to help prevent seasonal influenza infections.
The main types of vaccines in the inactivated influenza vaccine market include the trivalent inactivated influenza vaccine (TIIV) and the quadrivalent inactivated influenza vaccine (QIIV). The trivalent inactivated influenza vaccine contains three inactivated virus strains two influenza A strains and one influenza B strain to provide protection against seasonal influenza. These vaccines are used across various age groups, including children, adolescents, adults, and the elderly, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and public health clinics. End users include healthcare providers, individuals, government organizations, and pharmaceutical companies.
The inactivated influenza vaccine market research report is one of a series of new reports from The Business Research Company that provides inactivated influenza vaccine market statistics, including inactivated influenza vaccine industry global market size, regional shares, competitors with an inactivated influenza vaccine market share, detailed inactivated influenza vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the inactivated influenza vaccine industry. This inactivated influenza vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The inactivated influenza vaccine market size has grown strongly in recent years. It will grow from$6.62 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be attributed to increased seasonal influenza outbreaks, government vaccination campaigns, a rising elderly population, improved public health awareness, and the expansion of healthcare infrastructure.
The inactivated influenza vaccine market size is expected to see strong growth in the next few years. It will grow to$9.99 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to the rising demand for quadrivalent vaccines, the expansion of immunization programs, a growing focus on pandemic preparedness, technological advancements in vaccine production, and increasing global access to vaccines. Key trends during this period include a shift toward cell-based vaccine production, the growing adoption of adjuvanted formulations, the integration of influenza vaccines with COVID-19 boosters, rising demand in emerging markets, and the development of personalized vaccine strategies.
The growth of government vaccination programs is significantly boosting the inactivated influenza vaccine market. As public health awareness increases, governments are enhancing their immunization efforts, leading to greater demand for vaccines and more accessible immunization services. These programs play a critical role in providing free or subsidized inactivated influenza vaccines to high-risk groups, ensuring widespread vaccine coverage, and reducing the seasonal burden of influenza. For example, in December 2023, the UK's National Health Service (NHS) introduced a new vaccination strategy aimed at improving immunization outreach, particularly to underserved and marginalized communities. This strategy is designed to expand vaccination accessibility and further promote public health, which in turn is expected to drive growth in the inactivated influenza vaccine market.
Leading companies in the inactivated influenza vaccine market are increasingly focusing on the development of quadrivalent vaccines. These vaccines are designed to protect against four distinct strains of the influenza virus, offering broader protection and improving vaccine efficacy. For example, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent inactivated influenza vaccine that provides protection against four strains of the flu virus. By covering both influenza A and B strains, this vaccine reduces the risk of vaccine mismatch and enhances protection against seasonal flu outbreaks, while also tailoring immune responses to regional epidemiological trends.
In July 2024, GSK plc, a UK-based pharmaceutical company, expanded its capabilities in mRNA vaccine development by acquiring the full rights to develop, manufacture, and commercialize mRNA-based influenza and COVID-19 vaccines from CureVac N.V. for an undisclosed amount. This acquisition allows GSK to leverage CureVac's advanced mRNA research to improve seasonal flu vaccines and boost pandemic preparedness strategies. CureVac, a Germany-based biotechnology company, specializes in mRNA-based therapeutics, including vaccines for influenza and cancer immunotherapy.
Major players in the inactivated influenza vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis International, GlaxoSmithKline plc, Viatris Inc., CSL, Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Dalian Aleph Biomedical Co. Ltd., Hualan Biological Bacterin Co. Ltd, Changchun Biological, Jiangsu gdk Biotechnology Co., Ltd., KM Biologics, JoinHub Pharma, and Pharmika India Private Limited.
North America was the largest region in the inactivated influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated influenza vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the inactivated influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The inactivated influenza vaccine market consists of sales of adjuvanted inactivated influenza vaccines, preservative-free inactivated influenza vaccines, cell-based inactivated influenza vaccines, egg-based inactivated influenza vaccines, pediatric inactivated influenza vaccines, high-dose inactivated influenza vaccines for older adults, prefilled syringe vaccines, and multidose vial vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Inactivated Influenza Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on inactivated influenza vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for inactivated influenza vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inactivated influenza vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV); Quadrivalent Inactivated Influenza Vaccine (QIIV)
2) By Application: Children; Adolescence; Adults; Elderly
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Public Health Clinics
4) By End-User: Healthcare Providers; Individuals; Government Organizations; Pharmaceutical Companies
3. Inactivated Influenza Vaccine Market Trends And Strategies
4. Inactivated Influenza Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Inactivated Influenza Vaccine Growth Analysis And Strategic Analysis Framework
5.1. Global Inactivated Influenza Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Inactivated Influenza Vaccine Market Growth Rate Analysis
5.4. Global Inactivated Influenza Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Inactivated Influenza Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Inactivated Influenza Vaccine Total Addressable Market (TAM)
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Inactivated Influenza Vaccine Market
9.1. China Inactivated Influenza Vaccine Market Overview
9.2. China Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Inactivated Influenza Vaccine Market
10.1. India Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Inactivated Influenza Vaccine Market
11.1. Japan Inactivated Influenza Vaccine Market Overview
11.2. Japan Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Inactivated Influenza Vaccine Market
12.1. Australia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Inactivated Influenza Vaccine Market
13.1. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Inactivated Influenza Vaccine Market
14.1. South Korea Inactivated Influenza Vaccine Market Overview
14.2. South Korea Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Inactivated Influenza Vaccine Market
15.1. Western Europe Inactivated Influenza Vaccine Market Overview
15.2. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Inactivated Influenza Vaccine Market
16.1. UK Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Inactivated Influenza Vaccine Market
17.1. Germany Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Inactivated Influenza Vaccine Market
18.1. France Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Inactivated Influenza Vaccine Market
19.1. Italy Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Inactivated Influenza Vaccine Market
20.1. Spain Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Inactivated Influenza Vaccine Market
21.1. Eastern Europe Inactivated Influenza Vaccine Market Overview
21.2. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Inactivated Influenza Vaccine Market
22.1. Russia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Inactivated Influenza Vaccine Market
23.1. North America Inactivated Influenza Vaccine Market Overview
23.2. North America Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Inactivated Influenza Vaccine Market
24.1. USA Inactivated Influenza Vaccine Market Overview
24.2. USA Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Inactivated Influenza Vaccine Market
26.1. South America Inactivated Influenza Vaccine Market Overview
26.2. South America Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Inactivated Influenza Vaccine Market
27.1. Brazil Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Inactivated Influenza Vaccine Market
28.1. Middle East Inactivated Influenza Vaccine Market Overview
28.2. Middle East Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Inactivated Influenza Vaccine Market
29.1. Africa Inactivated Influenza Vaccine Market Overview
29.2. Africa Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Inactivated Influenza Vaccine Market Competitive Landscape And Company Profiles
